4:10 Bonus Issue, 1:10 Stock Split Declared: Zero-Debt Pharma Stock Rallies 484% In 2-Yrs

Small cap company engaged in pharmaceuticals sector Achyut Healthcare Ltd shares gained 31% in last 2-weeks. Last trading price of Achyut Healthcare shares on BSE is Rs 66.25 per share. The company on October 19, 2024 recommended 4:10 bonus shares and 1:10 stock split. The zero-debt burden stock has a market capitalisation of Rs 111.47 crore. This is the second bonus issue that Achyut Healthcare recommended in a span of 1-year. Check details below:

Achyut Healthcare Recommends Bonus Share: As per the BSE filing of Achyut Healthcare dated October 19, 2024, "the Board considered and recommended a bonus issue in the ratio of 04:10 i.e. Four new bonus Equity Share of Re.1/- each for every Ten existing fully paid up Equity Shares of Re.1/- each, subject to approval by the members and any other applicable statutory and regulatory approvals (Annexure III)."

Achyut Healthcare Approves Stock Split: The exchange filing of Achyut Healthcare issued as on October 19 added, "recommended the proposal for subdivision of Company's 1 (One) Equity Share of face value of Rs. 10/- (Rupees Ten only) each into Ten (10) equity shares of face value of Re.1/- (Rupee One only) each, subject to approval of Shareholders (Annexure I)."

Achyut Healthcare Shares Performance: The 52-week high price of Achyut Healthcare shares on BSE is Rs 71.90 per share (as on 17/10/2024) and 52-week low price is Rs 40.23 per share (as on 02/05/2024), respectively. Achyut Healthcare shares offered return of 30% in last 1-year, gained 20% in last 1-year, and rallied 484% in last 2-years.

Achyut Healthcare About: It is a leading pharmaceutical trading firm. It focuses on dealing in API, pharmaceutical products, and medical devices by offering healthcare services through innovation and technology.

Disclaimer: The stock highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.